TVRD
Price:
$4.18
Market Cap:
$39.21M
Tvardi Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases with significant unmet need. Their lead candidate, TTI-101, is currently in Phase 2 clinical trials for idiopathic pulmonary fibrosis (IPF) and hepatocellular carcinoma (HCC).
Industry
Biotechnology
IPO Date
2025-04-16
Stock Exchange
NASDAQ
Ticker
TVRD
According to Tvardi Therapeutics, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -1.86. This represents a change of -1.66% compared to the average of -1.89 of the last 4 quarters.
The mean historical PE Ratio of Tvardi Therapeutics, Inc. over the last ten years is -0.86. The current -1.86 PE Ratio has changed 21.58% with respect to the historical average. Over the past ten years (40 quarters), TVRD's PE Ratio was at its highest in in the June 2025 quarter at 11.54. The PE Ratio was at its lowest in in the September 2025 quarter at -16.53.
Average
-0.86
Median
-0.11
Minimum
-2.64
Maximum
0.77
Discovering the peaks and valleys of Tvardi Therapeutics, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 2.76%
Maximum Annual PE Ratio = 0.77
Minimum Annual Increase = -110.17%
Minimum Annual PE Ratio = -2.64
| Year | PE Ratio | Change |
|---|---|---|
| 2024 | -0.11 | -96.02% |
| 2023 | -2.64 | 18.42% |
| 2022 | -2.23 | 2.76% |
| 2021 | -0.08 | -110.17% |
The current PE Ratio of Tvardi Therapeutics, Inc. (TVRD) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
-1.66
5-year avg
-0.86
10-year avg
-0.86
Tvardi Therapeutics, Inc.’s PE Ratio is greater than CalciMedica, Inc. (-2987.83), greater than Lantern Pharma Inc. (-2.11), less than LAVA Therapeutics N.V. (-1.65), less than Actinium Pharmaceuticals, Inc. (-1.31), less than Elutia Inc. (-1.07), less than PDS Biotechnology Corporation (-1.20), less than Reviva Pharmaceuticals Holdings, Inc. (-1.09), greater than Xilio Therapeutics, Inc. (-2.53), less than Tempest Therapeutics, Inc. (-0.30), greater than FibroGen, Inc. (-16.14),
| Company | PE Ratio | Market cap |
|---|---|---|
| -2987.83 | $65.85M | |
| -2.11 | $42.17M | |
| -1.65 | $45.77M | |
| -1.31 | $45.23M | |
| -1.07 | $29.45M | |
| -1.20 | $43.78M | |
| -1.09 | $40.31M | |
| -2.53 | $38.90M | |
| -0.30 | $15.19M | |
| -16.14 | $33.37M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Tvardi Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Tvardi Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Tvardi Therapeutics, Inc.'s PE Ratio?
How is the PE Ratio calculated for Tvardi Therapeutics, Inc. (TVRD)?
What is the highest PE Ratio for Tvardi Therapeutics, Inc. (TVRD)?
What is the 3-year average PE Ratio for Tvardi Therapeutics, Inc. (TVRD)?
What is the 5-year average PE Ratio for Tvardi Therapeutics, Inc. (TVRD)?
How does the current PE Ratio for Tvardi Therapeutics, Inc. (TVRD) compare to its historical average?